From the HeartWire there was further follow-up of prior data looking at Pradaxa (dabigatran) versus Coumadin (warfarin) in mechanical heart valve patients. It would appear for now at least that the traditional treatment of warfarin is still in the driver’s seat in this situation.
It is the investigator’s theory that the anti-thrombin mechanism of action with dabigatran doesn’t appear to be as effective in mechanical valve replacement versus the clotting factors inhibition mechanism of warfarin. The implications for the other newer anticoagulant medications suggest warfarin may maintain the drug of choice status in this situation.
Have you ever considered creating an ebook or guest authoring on other sites?
I have a blog based on the same ideas you discuss and would really
like to have you share some stories/information. I know my visitors would appreciate your
work. If you’re even remotely interested, feel free to shoot me
an e-mail.
Follow this link to an e-mail I submitted for our local county physician association.
http://ipalc.org/e-recipe-health-book/
Dr. Kordonowy